In our study, we found that CD4+TIL increases post‐chemotherapy, and high post‐chemotherapy TIL has a significant survival benefit, which suggests that the addition of immunotherapy may prolong the survival of patients with NSCLC. This evidence concerns the gene CD4 and non-small cell lung carcinoma.